|
09 Nov 2021 |
EdiGene Enters Research Collaboration with the University of Wisconsin-Madison on In Vivo RNA Editing Therapies
|
|
04 Nov 2021 |
Dalriada Drug Discovery Celebrates Client Dunad Therapeutics Billion Dollar Collaboration with Novartis
|
|
04 Nov 2021 |
Alpha Tau Announces Enrollment of First Patient in Combination Trial of Alpha DaRT™ and Pembrolizumab (Keytruda®)
|
|
02 Nov 2021 |
Dunad Therapeutics enters Strategic Collaboration with Novartis to Develop Next-generation Oral Targeted Protein Degrader Therapies
|
|
01 Nov 2021 |
Venatorx Pharmaceuticals Announces Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen
|
|
01 Nov 2021 |
Imugene and Eureka Therapeutics Announce Strategic Collaboration to Accelerate Advancement of Oncolytic Virus and T-Cell Therapy in Solid Tumours
|
|
01 Nov 2021 |
Synthekine Establishes Collaboration with Merck to Develop Therapeutic Candidates Using its Proprietary Surrogate Cytokine Agonist Platform
|
|
28 Oct 2021 |
MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs
|
|
28 Oct 2021 |
Pan Cancer T Extends Seed Financing Round with Additional Funding from Existing Shareholders and New Investor Thuja Capital
|
|
28 Oct 2021 |
Agomab Therapeutics to Acquire Origo Biopharma
|
|
27 Oct 2021 |
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors
|
|
27 Oct 2021 |
Mozart Therapeutics Launches with $55 Million Series A Financing to Develop Disease Modifying Therapeutics for Autoimmune and Inflammatory Diseases
|
|
27 Oct 2021 |
Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders
|
|
27 Oct 2021 |
Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate
|
|
27 Oct 2021 |
Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
|
|
26 Oct 2021 |
Ubiquigent extends and expands drug discovery collaboration with Bristol Myers Squibb
|
|
25 Oct 2021 |
X-Chem Acquires ComInnex
|
|
21 Oct 2021 |
Mablink Bioscience and Emergence Therapeutics Enter Into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy
|
|
19 Oct 2021 |
Calithera Expands Oncology Pipeline with Acquisition of Two Clinical-Stage Assets from Takeda Pharmaceuticals
|
|
16 Oct 2021 |
Treadwell Therapeutics Announces Acquisition of TCRyption Inc., a Novel TCR-Based T Cell Therapy Company and TIO Bioventures Portfolio Company
|
|
16 Oct 2021 |
Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence's mRNAi GOLD™ Platform
|
|
14 Oct 2021 |
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
|
|
14 Oct 2021 |
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
|
|
14 Oct 2021 |
Immusoft and Takeda Collaborate to Discover and Develop Cell Therapies for Rare Neurometabolic Disorders
|
|
14 Oct 2021 |
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
|
